Gentolex’s story can be traced back to the summer of 2013, a group of young people with a vision in the industry to create opportunities connecting the world with better services and products guarantee.

about
Gentolex

Gentolex’s story can be traced back to the summer of 2013, a group of young people with a vision in the industry to create opportunities connecting the world with better services and products guarantee. Up to date, with years of accumulation, Gentolex Group has been serving customers from more than 15 countries across 5 continents, specially, representative teams are established in Mexico and South Africa, soon, more representative teams will be established for business services.

news and information

The sales comparision of Dulaglutide, Liraglutide and Semaglutide.

The sales comparision of Dulaglutide, Liraglutide and Semaglutide.

Pharmaceutical giant Lilly, an American company, and Novo Nordisk, a Danish company, have successively announced the sales data of their main products in 2020: Dulaglutide has become a TOP1 GLP-1 drug, with sales of $5.07Bn in 2020, a year-on-year increase of 22.8%; liraglutide Beginning to enter...

View Details
Does growth hormone slow or accelerate aging?

Does growth hormone slow or accelerate aging?

GH/IGF-1 decreases physiologically with age, and these changes are accompanied by fatigue, muscle atrophy, increased adipose tissue, and cognitive deterioration in the elderly… In 1990, Rudman published a paper in the New England Journal of Medicine that shocked the medical community –...

View Details
New Products Alert

New Products Alert

In order to provide more options to the clients in Cosmetic peptides industry, Gentolex will constantly add new products to the list. High quality with varieties categories, there are totally four different series defined by functions in protecting skins, including Anti-aging & anti-wrinkle, ...

View Details
Acadia Trofinetide Phase III Clinical Top-Line Results Positive

Acadia Trofinetide Phase III Clinical Top-Line Results Positive

On 2021-12-06, US time, Acadia Pharmaceuticals (Nasdaq: ACAD) announced the positive top-line results of its Phase III clinical trial of its drug candidate, Trofinetide. The phase III trial, called Lavender, is mainly used to evaluate the safety and efficacy of Trofinetide in the treatment of Ret...

View Details
The research progress of opioid peptides from the approval of Difelikefalin

The research progress of opioid peptides from the approval of Difelikefalin

As early as 2021-08-24, Cara Therapeutics and its business partner Vifor Pharma announced that its first-in-class kappa opioid receptor agonist difelikefalin (KORSUVA™) was approved by the FDA for the treatment of chronic kidney disease (CKD) patients (positive Moderate/severe pruritus with hemod...

View Details